2784
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

Alfresa Holdings Corporation is a holding company that manages a group of subsidiaries engaged in the pharmaceutical and healthcare sectors. The group's primary business segments include the wholesale distribution of medical pharmaceuticals, diagnostic reagents, and medical devices, led by Alfresa Co., Ltd. and regional subsidiaries such as Shikoku Alfresa, TS Alfresa, Meisho, Ryu-Yaku, and Tohoku Alfresa. The Self-Medication wholesale segment, operated by Alfresa Healthcare, distributes general pharmaceuticals, health foods, and related products. In the manufacturing segment, Alfresa Pharma produces pharmaceuticals, diagnostic reagents, medical devices, and APIs, supported by subsidiaries including Qingdao Naisike Medical Devices Co., Ltd. and Alfresa Fine Chemical. The group also operates a chain of community pharmacies through Apocrite. Additional business activities include SPD (Supply Processing and Distribution) services for hospital logistics, CRO and PMS services via ArkMS, and the development of regenerative medicine products and cell materials by Cell Resources. The company also provides IT system operations and maintenance through Alfresa System and engages in insurance agency and real estate management via Alfresa Biz Support.

Summarised from the annual report, fiscal year ended Mar 2026

Industry Medical Distribution Homepage alfresa.com
Sector Healthcare IR page alfresa.com
Tags
pharmaceutical wholesale, medical devices, diagnostic reagents, pharmacy operations, pharmaceutical manufacturing, apis, spd services, cro, pms, regenerative medicine, health foods, Alfresa Co. Ltd., Shikoku Alfresa, TS Alfresa, Meisho, Ryu-Yaku, Tohoku Alfresa, Alfresa Medical Service, Alfresa Shinohara Chemical, S.M.D., A.L. Plus, Miyazaki Onsendo Shoten, Techno Suzuta, Alfresa Healthcare, Alfresa Pharma, Qingdao Naisike Medical Devices Co. Ltd., Alfresa Fine Chemical, Apocrite, Alfresa System, Cell Resources, ArkMS, Alfresa Biz Support
Press page alfresa.com/ir/news

Metrics

Valuation  
Market cap ¥ 436.355B
Market cap (USD) $ 2.727B
P/E 10.72
PEG 0.62
P/BV 0.88
P/S 0.14
P/OCF 9.80
P/FCF 20.04
Dividend yield 3.0%
Turnover / mcap —
Returns  
ROE 8.4%
ROI 8.1%
ROIC 4.7%
Profit margin 1.3%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 17.4%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 22.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 3.104T 2.961T 2.859T 2.696T 2.586T 2.603T 2.699T 2.641T 2.603T 2.552T 2.576T 2.421T 2.505T 2.388T
Net profit 41.746B 27.389B 29.558B 25.786B 32.182B 24.501B 40.273B 41.699B 35.589B 30.893B 34.975B 22.922B 25.566B 20.771B
Free cash flow 10.041B -14.489B 71.051B -12.379B 19.558B -39.402B 13.252B 33.211B 35.207B 20.734B 23.593B — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 2.527K 2.109K 2.222K 1.694K 1.702K 2.131K 2.013K 3.149K 2.368K 1.928K 2.16K 1.693K 1.685K 1.274K
Price performance 12m 0.2 -0.05 0.31 -0 -0.2 0.06 -0.36 0.33 0.23 -0.11 0.28 0 0.32 —

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Trade receivables (JPY) 602B 613B 614B 595B 592B 602B 624B 646B 646B 683B
↳ YoY growth -1.7% +1.8% +0.2% -3.1% -0.5% +1.7% +3.5% +3.6% -0.1% +5.7%
↳ 5y CAGR -0.7% +0.0% +0.3% +1.0% +1.6% +2.9%
Other receivables (JPY) 52.8B 76.5B 80.3B 77.8B 80.1B 76.7B 82.1B 87.2B 84.4B 93.5B
Borrowings, current (JPY) 549M 859M 760M 570M 240M 48M — — — —
Borrowings, non-current (JPY) 1.29B 1.21B 951M 630M 389M — — 30B 30B 30B
Bonds payable (JPY) — — — — — — — 20B 20B 20B
Lease liabilities (JPY) 4.72B 4.58B 5.04B 5.97B 5.54B 4.99B 3.86B 4.94B 5.55B 5.62B
Cash and deposits (JPY) 164B 192B 206B 211B 170B 180B 160B 214B 177B 193B
Intangible assets (JPY) 13.8B 12.1B 17.4B 17.6B 17.4B 18.8B 17.9B 16.6B 11.5B 13.1B
Net debt (borrowings + leases - cash) (JPY) -158B -185B -200B -203B -164B -175B — -179B -142B -157B
Cash flow detail
Operating cash flow (JPY) 34.3B 47.6B 46.9B 33.8B -21.2B 36.5B 13.1B 86.4B 5.64B 38.6B
Purchases of property, plant and equipment (JPY) -10.6B -9.8B -11.2B -19B -15.1B -15B -22.7B -12.7B -16.5B -22.5B
Purchases of intangible assets (JPY) -2.96B -2.57B -2.47B -1.58B -3.16B -1.99B -2.75B -2.59B -3.62B -6.07B
Change in receivables (cash effect) (JPY) 12.8B -36.1B -3.02B 19.9B 4.19B -7.47B -26.4B -25.2B 2.52B -44.2B
Change in inventories (cash effect) (JPY) 2.79B -1.44B 1.46B -15.2B 933M 1.65B -5.9B -3.58B -11.2B -5.18B
Change in payables (cash effect) (JPY) -11B 29.4B 1.15B -18.7B -45B 951M 25.1B 75B -24.3B 47.1B
Dividends paid (cash effect) (JPY) -7.37B -8.23B -9.41B -10.4B -10.8B -11.4B -11.1B -12.2B -12.6B -12B
Share buybacks (cash effect) (JPY) -3M -4M -13.3B -2M -2M -15.3B -2M -35.7B -11B -638M
Interest paid (cash effect) (JPY) -103M -93M -92M -98M -85M -73M -64M -132M -278M -355M
Income taxes paid (cash effect) (JPY) -21.2B -10.4B -17.6B -21.8B -18.1B -9.02B -18.1B -12.3B -14.3B -13B
Operating cash flow before change in receivables (JPY) 21.5B 83.7B 49.9B 13.9B -25.4B 44B 39.5B 112B 3.12B 82.7B
Free cash flow (OCF - PPE - intangibles) (JPY) 20.7B 35.2B 33.2B 13.3B -39.4B 19.6B -12.4B 71.1B -14.5B 10B
Income detail
Research and development expense (JPY) 1.14B 1.16B 1.25B 1.4B 1.44B 1.37B 2.09B 2.2B 1.9B 2.33B
↳ 5y CAGR +5.1% +3.8% +12.6% +12.0% +6.3% +10.1%
Total comprehensive income (JPY) 34.6B 50.2B 29.8B 43.5B 27.1B 8.46B 27.6B 39B 25.4B 39.3B
Comprehensive income to owners (JPY) 34.3B 50.1B 29.8B 43.4B 27.1B 8.44B 27.6B 39B 25.3B 39.2B
Provision for credit losses (JPY) — — 205M 1.5B -608M 1.25B -386M -1.16B 192M 338M
Credit cost ratio (credit losses / average receivables) (%) — — 0.0% 0.2% 0.1% 0.2% 0.1% 0.2% 0.0% 0.0%
Segments
Dispensing Pharmacy And Related Businesses · Segment revenue (JPY) — — — — — — — — 37B 37.2B
↳ YoY growth +0.4%
Dispensing Pharmacy And Related Businesses · Segment operating income (JPY) — — — — — — — — 596M 499M
Reported Jun 27, 2017 Jun 26, 2018 Jun 25, 2020 Jun 25, 2020 Jun 25, 2021 Jun 28, 2022 Jun 27, 2023 Jun 26, 2024 Jun 23, 2026 Jun 23, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Alfresa Holdings Corporation (ticker 2784), listed in Japan.

ETFs Holding Alfresa Holdings Corporation

ETF Weight in ETF Shares Market value As of
AVDV 0.21% 2,797,400 $ 41.127M Nov 16, 2026
DISV 0.17% 591,501 $ 8.49M Nov 12, 2026
AVDS 0.10% 24,400 $ 358.724K Nov 16, 2026
DFIS 0.06% 249,401 $ 3.58M Nov 12, 2026
AVSD 0.05% 11,500 $ 169.071K Nov 16, 2026
AVDE 0.03% 422,700 $ 6.214M Nov 16, 2026
DXIV 0.03% 4,900 $ 70.328K Nov 12, 2026
DFSI 0.02% 18,300 $ 262.655K Nov 12, 2026
DFIC 0.02% 206,000 $ 2.957M Nov 12, 2026
DFAX 0.01% 117,500 $ 1.686M Nov 12, 2026
DFIV 0.01% 164,701 $ 2.364M Nov 12, 2026
DFAI 0.01% 118,100 $ 1.695M Nov 12, 2026